Novo Nordisk A/S $NVO Shares Acquired by Keybank National Association OH

Keybank National Association OH boosted its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 28.8% in the third quarter, HoldingsChannel reports. The fund owned 74,170 shares of the company’s stock after purchasing an additional 16,582 shares during the quarter. Keybank National Association OH’s holdings in Novo Nordisk A/S were worth $2,812,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S during the 1st quarter valued at about $287,660,000. State Street Corp raised its stake in Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after buying an additional 32,641 shares during the last quarter. Royal Bank of Canada raised its stake in Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock valued at $166,396,000 after buying an additional 141,376 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after acquiring an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Novo Nordisk A/S by 6.7% during the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock worth $124,844,000 after acquiring an additional 213,443 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, September 10th. Barclays reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. BMO Capital Markets set a $40.00 target price on shares of Novo Nordisk A/S and gave the stock a “market perform” rating in a research report on Monday, October 12th. Finally, Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $59.44.

Read Our Latest Report on Novo Nordisk A/S

More Novo Nordisk A/S News

Here’s some of the latest news about NVO:

  • Positive Sentiment: Novo submitted U.S. and European applications for etavopivat, an investigational once-daily oral treatment for sickle cell disease in patients aged 12 and older. The filings add a potential product opportunity beyond the company’s diabetes and obesity business, but the drug is not yet approved. Novo submits etavopivat to the FDA and EMA
  • Neutral Sentiment: Novo enlisted DJ Khaled to share his Wegovy experience as part of a U.S. promotional campaign. The partnership could raise awareness, though its impact on prescriptions and sales is uncertain. Novo and DJ Khaled team up to promote Wegovy
  • Negative Sentiment: Eli Lilly secured China’s first approval for an oral GLP-1 weight-loss drug, giving it an early lead in a major market while Novo’s own oral product has yet to launch there. The development highlights intensifying competition in obesity treatment. Eli Lilly beats Novo to oral China GLP-1 market

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $41.65 on Monday. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a 50 day simple moving average of $40.09 and a two-hundred day simple moving average of $43.34. The stock has a market cap of $185.99 billion, a price-to-earnings ratio of 10.49, a PEG ratio of 1.43 and a beta of 0.70.

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.

Further Reading

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.